VRNA

VRNA

USD

Verona Pharma plc American Depositary Share

$106.910+0.060 (0.056%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigtes Königreich

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$106.850

Hoch

$106.910

Tief

$106.910

Volumen

1.87M

Unternehmensfundamentaldaten

Marktkapitalisierung

9.1B

Branche

Biotechnologie

Land

United Kingdom

Handelsstatistiken

Durchschnittliches Volumen

1.69M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $31.6Aktuell $106.910Hoch $106.93

Ähnliche Nachrichten

Analyst Upgrades

Cantor Fitzgerald Suspends Overweight Rating on Verona Pharma PLC ADR, Maintains $100 Price Target

Cantor Fitzgerald suspends Overweight rating on Verona Pharma PLC ADR and Maintains $100 price target

Mehr anzeigen
Cantor Fitzgerald Suspends Overweight Rating on Verona Pharma PLC ADR, Maintains $100 Price Target
BusinessWire

Merck Completes Acquisition of Verona Pharma

Acquisition strengthens Merck's cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck (NYSE:MRK),

Mehr anzeigen
Merck Completes Acquisition of Verona Pharma
GlobeNewswire

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on

Mehr anzeigen
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
GlobeNewswire

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive

Mehr anzeigen
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck